Table 1 Basic HIV Medical history and clinical characteristics
From: Camrelizumab for cancers in patients living with HIV: one-single center experience
Patients (N = 24) (% or median) | |
|---|---|
Median age | 59 (41–75) |
Gender | |
Male | 21 (88%) |
Female | 3 (12%) |
CDC | |
A | 6 (25.0%) |
B | 5 (21%) |
C | 3 (12%) |
Unknown | 10 (42%) |
ECOG performance status | |
0 | 15 (62%) |
1 | 9 (37%) |
Baseline CD4+ count | 528.3/uL (125–1309) |
Baseline CD4+/CD8+ ratio | 1.26 (0.22–4.12) |
ART | |
With | 23 (96%) |
Without | 1 (4%) |
ART regimen | |
PI-based regimen | 15 (62%) |
NNRTI-based regimen | 8 (32%) |
INSTI-based regimen | 1 (4%) |
Duration of ART (year) | 2.94 (0–9) |
Baseline HIV viral load | |
Undetectable | 23 (96%) |
>40 copies/mL | 1 (4%) |
Baseline laboratory test (before ICPs) | |
WBC | 8.16 (2.68029.9) |
HGB | 123.91 (66–160) |
PLT | 246.67 (68–539) |
ALT | 21.88 (7–87) |
AST | 25.88 (13–74) |
TBIL | 14.80 (4.5–42.3) |
Serum creatine (umol/L) | 112.87 (47–933) |
eGFR | 88.217 (4.7-116.3) |
Combined with chemotherapy | |
Yes | 6 (25%) |
No | 18 (75%) |
Previous therapy | |
Radiotherapy | 2 (8%) |
Chemotherapy | 6 (25%) |
Surgery | 10 (42%) |
None | 6 (25%) |